Lercanidipina Accord

Lercanidipine, the active ingredient in Lercanidipina Accord, is a calcium channel blocker presented as an oral dosage form for oral use. It is employed to lower elevated blood pressure in adults diagnosed with hypertension. GNH USA supplies Lercanidipina Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lercanidipine is a dihydropyridine calcium‑channel blocker indicated for the management of hypertension, helping to achieve controlled blood pressure levels.

Hypertension: reduces systemic vascular resistance and lowers arterial pressure, improving cardiovascular risk profile.

Lercanidipine may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Headache - Flushing - Peripheral edema - Dizziness - Tachycardia - Nausea

Serious or Rare Side Effects: - Severe hypotension - Myocardial infarction - Angioedema - Hepatic injury - Severe bradycardia - Anaphylactic reactions

Before initiating therapy, clinicians should consider several safety aspects. - Blood pressure monitoring: check baseline and periodic readings to avoid excessive hypotension. - Hepatic function: use caution in patients with moderate to severe liver impairment. - Concomitant antihypertensives: adjust doses to prevent additive blood‑pressure lowering effects. - Heart failure: evaluate for fluid retention and monitor cardiac status. - Discontinuation: avoid abrupt cessation; taper if clinically indicated. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Lercanidipine can interact with several drug classes, influencing its efficacy and safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase plasma concentrations. - Other calcium‑channel blockers: additive vasodilatory effect can cause profound hypotension. - Grapefruit juice: enhances systemic exposure, raising risk of adverse events. - Concurrent antihypertensives with potent vasodilatory action: may lead to unsafe blood‑pressure drops.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce therapeutic levels. - Diuretics: monitor electrolytes and volume status. - Non‑steroidal anti‑inflammatory drugs (NSAIDs): can blunt antihypertensive response. - Beta‑blockers: observe for bradycardia and excessive blood‑pressure reduction.